Showing results (151-160 of 177) with videos related to
Sort By:
Pageof 18
Blood|July 14, 2011
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activationRieneke van de Ven, Mari F C M van den Hout, Jelle J Lindenberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumorsGiuseppe Giaccone, Cornelis J A Punt, Yoshitaka Ando, et al.Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|August 10, 2013
Autologous skin substitute for hard-to-heal ulcers: retrospective analysis on safety, applicability, and efficacy in an outpatient and hospitalized settingChantal S Blok, Liselot Vink, Edith M de Boer, et al.The Journal of Pharmacology and Experimental Therapeutics|January 12, 2012
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritisSue Ellen Verbrugge, Yehuda G Assaraf, Ben A C Dijkmans, et al.Journal of Translational Medicine|February 14, 2013
IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cellsSaskia J A M Santegoets, Annelies W Turksma, Megan M Suhoski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patientsBarbara G Molenkamp, Berbel J R Sluijter, Paul A M van Leeuwen, et al.International Journal of Cancer|March 10, 2005
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor loadJohan W Molling, Wendy Kölgen, Hans J J van der Vliet, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2006
Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infectionHans J J van der Vliet, Marit G A van Vonderen, Johan W Molling, et al.Journal of Hepatology|June 30, 2007
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis CBart J Veldt, Hans J J van der Vliet, B Mary E von Blomberg, et al.Cancer Immunology Research|September 23, 2017
Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and RecurrenceMari F C M van den Hout, Bas D Koster, Berbel J R Sluijter, et al.Pageof 18